If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
174
results.
Updated on
29/08/2025 [06:52:00]
Results 75 to 100 of 174
Absstract of: AU2024213596A1
A method of treating a pulmonary condition in a subject having or at risk of having the pulmonary condition generally includes administering to the subject a therapeutic composition in an amount effective to treat the pulmonary' condition. Generally, the therapeutic composition includes purified exosome product (PEP) exosomes and a pharmaceutically acceptable carrier. In one or more embodiments, the PEP exosomes are modified to include at least one exogenous active agent. In one or more embodiments, the therapeutic composition is formulated for delivery directly to a potion of tire pulmonary tract.
Absstract of: US2025263385A1
The present invention provides, in part, second generation “good” buffer-based cationic lipids of Formula (I), and subformulas thereof: Formula (I), (t), or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins.
Absstract of: WO2025171862A1
Selenium nanoparticles for use in preventing, reducing risk of developing or treating epilepsy in a subject in need thereof, wherein selenium nanoparticles are administered parenterally to the subject, together with a transient disruption of the blood-brain barrier (BBB) of the subject.
Absstract of: WO2025172829A1
The invention focuses on creating chimeric peptosomes combined with gold nanoparticles and fitted with aptamers for targeted therapy and imaging of breast cancer. It aims to solve the problem of effectively targeting breast cancer cells without harming healthy cells. The method uses a special polypeptide made of polyethylene glycol (PEG) and poly(γ-benzyl L-glutamate) (PGBLG) to form a peptosome with a strong core for containing the chemotherapy drug doxorubicin. The peptosome is designed for controlled release of the drug and also allows for the inclusion of gold nanoparticles. The EpCAM aptamer is used to target cancer cells more precisely, improving therapy effectiveness and imaging through the unique properties of gold nanoparticles. This new platform enhances treatment success while minimizing side effects, representing a major advance in targeted cancer therapy.
Absstract of: MX2025001257A
Provided are a metal-phospholipid complex, a metal-phospholipid complex particle, a drug-lipid particle, a method for preparing same, and use thereof, which relate to the field of biotechnology. The metal-phospholipid complex is formed by reacting a phospholipid molecule portion, a linker molecule portion and a metal ion portion. The metal-phospholipid complex particle comprises the metal-phospholipid complex, a conjugated lipid that inhibits particle aggregation, and a non-cationic lipid or a non-ionizable lipid. The drug-lipid particle comprises a drug and the metal-phospholipid complex particle. The metal-phospholipid complex is used for adsorbing a drug with negative charges, and is self-assembled with other components to form the metal-phospholipid complex particle (MPP); the cationic lipid and the ionizable lipid are not used under the condition of being not lower than the effectiveness of the LNP based on the cationic lipid and/or the ionizable lipid; compared to the LNP, the toxicity is greatly reduced, and the biological safety is significantly improved, thereby better facilitating carry of negative-charge drugs in an organism.
Absstract of: TW202508605A
The present invention provides a composition for treating cancer comprising a DDB2 inhibitor and a chemotherapeutic agent, in which the DDB2 inhibitor comprises three RNA fragments from lincRNA-p21. In addition, the DDB2 inhibitor enhances the chemosensitivity of the cancer to the chemotherapeutic agent for treating cancers that do not respond to chemotherapy.
Absstract of: CN119947710A
The present invention relates to a method for determining the efficiency of RNA encapsulation in lipid nanoparticles (LNPs). In some embodiments, a method according to the invention comprises the steps of a) contacting a sample comprising RNA encapsulated in LNP with a first fluorophore and a second fluorophore, thereby forming a fluorophore-RNA complex, and b) detecting a fluorescence signal of the complexed first and second fluorophore, wherein the first fluorophore permeates the LNPs and wherein the second fluorophore does not permeate the LNPs.
Absstract of: WO2024033546A1
Magnetic polymer nanocapsules and their use in anti-cancer therapy have been disclosed, which are core-shell polymer nanocapsules carrying hydrophobic active substances, containing magnetic iron oxide nanoparticles.
Absstract of: EP4603589A2
The present disclosure includes cationic carrier units comprising (i) a water soluble polymer, (ii) a positively charged carrier, and (iii) an adjuvant moiety, wherein when the cationic carrier unit is mixed with an anionic payload (e.g., an antisense oligonucleotide) that electrostatically interacts with the cationic carrier unit, the resulting composition self-organizes into a micelle encapsulating the anionic payload in its core. The cationic carrier units can also comprise a tissue specific targeting moiety, which would be displayed on the surface of the micelle. The disclosure also includes micelles comprising the cationic carrier units of the disclosure, methods of manufacture of cationic carrier units and micelles, pharmaceutical compositions comprising the micelles, and also methods of treating diseases or conditions comprising administering the micelles to a subject in need thereof.
Absstract of: WO2024081668A2
Described herein are compounds comprising a lipid connected to a backbone of a polymer with functional groups. Also described herein is the use of such reagents for delivering nucleic acids to a cell.
Absstract of: WO2024079756A2
The invention relates to formulation for oral delivery of peptides and/or drug molecules and a method of manufacturing the same. The oral formulation is useful for delivering peptides to the gastrointestinal tract, preferably at the ileo-caecal junction of colon.
Absstract of: WO2024077376A1
Acute myeloid leukemia (AML) has not benefited from innovative immunotherapies, mainly because of the lack of actionable immune targets. Novel tumor-specific antigens (TSAs) shared by a large proportion of AML cells are described herein. Most of the TSAs described herein derives from aberrantly expressed unmutated genomic sequences, such as intronic and intergenic sequences, which are not expressed in normal tissues. Nucleic acids, compositions, cells and vaccines derived from these TSAs are described. The use of the TSAs, nucleic acids, compositions, cells and vaccines for the treatment of myelodysplastic syndrome (MDS) or leukemia such as AML is also described.
Absstract of: AU2023360051A1
The invention relates to oligonucleotides that inhibit Toll-Like Receptor 7 (TLR7) and/or Toll-Like Receptor 8 (TLR8), or potentiate TLR8, and uses thereof.
Absstract of: EP4603108A1
The present invention relates to a mannose-HSA based nanocarrier system, and a pharmaceutical composition containing the same for delivery of immunomodulatory drugs into target cells expressing surface mannose receptors. The present invention further relates to a method of manufacturing said mannoseHSA nanocarrier system.
Absstract of: WO2024095144A1
The present application relates to lipidic nanoparticles that are suitable for the treatment of neurologic or chronic diseases. The lipidic nanoparticles of the present application are of the solid lipid nanoparticles or nanostructured lipid carriers and comprise an encapsulated drug with a sustained and controlled drug delivery in the treatment of neurologic or chronic diseases.
Absstract of: MX2025004314A
The present invention relates to compounds of formula (I). The invention also extends to micro- or nanoparticles comprising a compound of formula (I). For instance, compounds of formula (I) can be used to produce stable lipid nanoparticles (LNPs). The LNPs have high encapsulation efficiency and can be used to deliver a therapeuticor prophylactic agent to a patient.
Absstract of: AU2023361222A1
The present invention relates to pharmaceutical compositions comprising at least one lipid nanopartide (LNP) specific for targeting Langerhans cells (LC) wherein the LNP encapsulates at least one mRNA, is capable of specifically binding to the receptor Langerin and facilitates Langerin-mediated uptake and intracellular delivery of said mRNA molecule and its translation into at least one protein or peptide. Further envisaged is the pharmaceutical composition for use in the treatment of cancer, of an autoimmune disease, of a bacterial infection, of a viral infection, of a fungal infection or of a graft-vs. host disease, of a local or systemic inflammation, of an allergy, or for hyposensitization.
Absstract of: US2025177305A1
A method of producing a lipid-encapsulated RNA nanoparticle, comprising the steps a) flowing an aqueous solution comprising an RNA through a 1st tube having an inner diameter (ID) of between about 0.1″ and 0.132″; b) flowing an ethanol solution comprising lipids through a 2nd tube having an ID of between about 0.005″ and 0.02″ at one third the flow rate of the aqueous solution through the 1st tube, wherein the lipids comprise a cationic lipid; and c) mixing the ethanol solution with the aqueous solution by flowing the ethanol solution and the aqueous solution into a mixing module consisting of the 2nd tube perpendicularly joined to the 1st tube; wherein the mixing produces an output solution flowing in the 1st tube comprising a turbulent flow of the RNA and the lipids in between about 10% to 75% ethanol v/v, and wherein the lipid-encapsulated RNA nanoparticles have a bilayer structure.
Absstract of: CN119654167A
The present disclosure relates generally to the field of nucleic acid (e.g., DNA or RNA, particularly mRNA) compositions comprising amphiphilic oligomeric ethylene glycol (OEG) conjugated compounds (as substitutes for PEG lipids); uses of such compositions, in particular for delivering nucleic acids to cells of a subject or for therapy; to an amphiphilic OEG conjugated compound of this type; and conjugates of such amphiphilic OEG conjugated compounds.
Absstract of: WO2024032482A1
The present disclosure relates to the technical field of biopharmaceutics, and particularly provides a metal-polyphenol compound particle, a drug-lipid particle, a method for preparing same, and use thereof. The metal-polyphenol compound provided in the present disclosure serves as a drug carrier for drug stabilization, delivery and transportation and the like, and forms, together with other carriers, the metal-polyphenol complex particle for achieving effective administration of negatively-charged drugs. The complex can achieve efficient systemic drug delivery and, compared with LNP containing cationic lipids or ionizable lipids, has significantly reduced toxicity, achieving safe and effective treatment of diseases or conditions.
Absstract of: US2025090471A1
The disclosure provides lipid nanoparticle (LNP) compositions of ionizable lipids, helper lipids, neutral lipids, and PEG lipids useful for the delivery of biologically active agents, for example delivering biologically active agents to cells to prepare engineered cells. The LNP compositions disclosed herein are useful in methods of gene editing and methods of delivering a biologically active agent and methods of modifying or cleaving DNA.
Absstract of: CN120501719A
本发明涉及药物制剂技术领域，尤其涉及基于CMCS封装的多孔金纳米壳在紫杉醇药物输送上的应用。本技术方法为将通过CMCS封装的多孔金纳米壳作为紫杉醇药物的载体，从而能够在使用时实现对PTX的pH响应性释放。本发明提供的基于CMCS封装性多孔金纳米壳在紫杉醇药物输送上的应用，将多孔金纳米壳与紫杉醇药物混合，并通过CMCS进行封装形成的CMCS/PTX/EHGNs，能够在癌症治疗时提升其水溶性和生物利用度。
Absstract of: CN120501722A
本发明适用于生物医药技术领域，提供了一种载有酚醛网络的白蛋白纳米粒子的制备方法及应用。本发明通过将表没食子儿茶素没食子酸酯‑铜(EGCG‑Cu)金属酚醛网络(EC NPs)负载于牛血清白蛋白纳米粒子(BSANPs)内，构建了一种智能纳米输送体系(BEC NPs)。该体系可特异性靶向炎症部位中性粒细胞，响应炎症微环境释放EC NPs，通过清除活性氧、抑制中性粒细胞外陷阱形成、促进巨噬细胞向M2型极化、抑制细胞焦亡等机制改善炎症微环境，缓解炎症损伤。体内实验显示BEC NPs能促进牙槽骨再生和牙周组织修复，生物相容性良好，为慢性牙周炎提供了兼具抗炎、免疫调控和组织修复功能的纳米治疗策略。
Absstract of: CN120505342A
本发明提供了一种环状多倍串联RNA正义链，其包括至少一个正义链序列和至少一个间隔序列。该环状RNA衍生自含有所有必需序列的工程化亲本DNA模板，其按以下顺序包括第一环化元件、任选地至少一个第一限制性酶识别序列、至少一个靶序列、任选地至少一个第二限制性酶识别序列和第二环化元件。该环状多倍串联RNA正义链可以结合并递送多个反义链RNA，在利用环状RNA稳定性优势的同时增加正义链和反义链的结合。
Nº publicación: CN120501756A 19/08/2025
Applicant:
中山大学孙逸仙纪念医院
Absstract of: CN120501756A
本发明公开了一种药物组合物，其包含环状RNA以及药物递送载体。与传统线性1×siRNA和环状1×siRNA相比，本公开将正义链重复串联数量增加到包括但不限于2个以上，意外地发现显著增强了沉默效果，能够显著降低PCSK9基因的表达水平，介导PCSK9蛋白的mRNA的降解。使用纳米颗粒递送寡核苷酸，增加了稳定性，降低了免疫原性，提高了降胆固醇、减少主动脉斑块负荷、抗动脉粥样硬化的作用，且安全无明显肝肾毒性，在制备高胆固醇血症、冠心病的治疗药物方面具有广阔的应用前景。
BOPI
Electronic site
